Abstract:
:Recombinant antibody single-chain variable fragments (scFv) are difficult to purify homogeneously from a protein complex mixture. The most effective, specific and fastest method of purification is an affinity chromatography on Protein L (PpL) matrix. This protein is a multi-domain bacterial surface protein that is able to interact with conformational patterns on kappa light chains. It mainly recognizes amino acid residues located at the VL FR1 and some residues in the variable and constant (CL) domain. Not all kappa chains are recognized, however, and the lack of CL can reduce the interaction. From a scFv composed of IGKV10-94 according to IMGT®, it is possible, with several mutations, to transfer the motif from the IGKV12-46 naturally recognized by the PpL, and, with the single mutation T8P, to confer PpL recognition with a higher affinity. A second mutation S24R greatly improves the affinity, in particular by modifying the dissociation rate (kd). The equilibrium dissociation constant (KD) was measured at 7.2 10(-11) M by surface plasmon resonance. It was possible to confer PpL recognition to all kappa chains. This protein interaction can be modulated according to the characteristics of scFv (e.g., stability) and their use with conjugated PpL. This work could be extrapolated to recombinant monoclonal antibodies, and offers an alternative for protein A purification and detection.
journal_name
MAbsjournal_title
mAbsauthors
Lakhrif Z,Pugnière M,Henriquet C,di Tommaso A,Dimier-Poisson I,Billiald P,Juste MO,Aubrey Ndoi
10.1080/19420862.2015.1116657subject
Has Abstractpub_date
2016-01-01 00:00:00pages
379-88issue
2eissn
1942-0862issn
1942-0870journal_volume
8pub_type
杂志文章相关文献
mAbs文献大全abstract::Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pe...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.2.2.11271
更新日期:2010-03-01 00:00:00
abstract::Monoclonal antibodies (mAbs) are a burgeoning class of therapeutics, with more than 25 approved in countries worldwide. Novel molecules are entering clinical study at a rate of nearly 40 per year, and the commercial pipeline includes approximately 240 mAb therapeutics in clinical studies that have not yet progressed t...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.2.1.10677
更新日期:2010-01-01 00:00:00
abstract::Monoclonal antibodies constitute a robust class of therapeutic proteins. Their stability, resistance to stress conditions and high solubility have allowed the successful development and commercialization of over 40 antibody-based drugs. Although mAbs enjoy a relatively high probability of success compared with other t...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.25269
更新日期:2013-09-01 00:00:00
abstract::The importance of antibodies in activating immune responses against tumors is now better appreciated with the emergence of checkpoint blockade antibodies and with engineered antibody Fc domains featuring enhanced capacity to focus potent effector cells against cancer cells. Antibodies designed with Fc regions of the I...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.27029
更新日期:2014-01-01 00:00:00
abstract::CD4(+) CD25(+) regulatory T cells are expanded in solid and hematological malignancies including chronic lymphocytic leukemia (CLL). Several cytokines and co-stimulatory molecules are required for generation, survival and maintenance of their suppressive effect. We and others have shown direct cytotoxic effect of the ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.2.1.10561
更新日期:2010-01-01 00:00:00
abstract::Complex cellular targets such as G protein-coupled receptors (GPCRs), ion channels, and other multi-transmembrane proteins represent a significant challenge for therapeutic antibody discovery, primarily because of poor stability of the target protein upon extraction from cell membranes. To assess whether a limited set...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2020.1755069
更新日期:2020-01-01 00:00:00
abstract::We describe protein synthesis, folding and assembly of antibody fragments and full-length aglycosylated antibodies using an Escherichia coli-based open cell-free synthesis (OCFS) system. We use DNA template design and high throughput screening at microliter scale to rapidly optimize production of single-chain Fv (scFv...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.4.2.19202
更新日期:2012-03-01 00:00:00
abstract::A dual-specific, tetravalent immunoglobulin G-like molecule, termed dual variable domain immunoglobulin (DVD-Ig™), is engineered to block two targets. Flexibility modulates Fc receptor and complement binding, but could result in undesirable cross-linking of surface antigens and downstream signaling. Understanding the ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.24258
更新日期:2013-05-01 00:00:00
abstract::Site-specific antibody-drug conjugates (ADCs) are designed to overcome the heterogeneity observed with first-generation ADCs that use random conjugation to surface-exposed lysine residues or conjugation to interchain disulfide bonds. Despite significantly enhanced homogeneity, however, the production of site-specific ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2019.1624127
更新日期:2019-08-01 00:00:00
abstract::Accurate measurement and functional characterization of antibody Fc domain N-linked glycans is critical to successful biosimilar development. Here, we describe the application of methods to accurately quantify and characterize the N-linked glycans of 2 IgG1 biosimilars with effector function activity, and show the pot...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1016692
更新日期:2015-01-01 00:00:00
abstract::Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues allows its exploitation as a tumor-associated antigen. The use of thes...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2018.1494105
更新日期:2018-10-01 00:00:00
abstract::Bispecific antibody therapeutics can expand the functionality of a conventional monoclonal antibody drug because they can bind multiple antigens. However, their great potential is counterbalanced by the challenges faced in their production. The classic asymmetric bispecific containing an Fc requires the expression of ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2018.1519631
更新日期:2018-11-01 00:00:00
abstract::Biosimilars are designed to be highly similar to approved or licensed (reference) biologics and are evaluated based on the totality of evidence from extensive analytical, nonclinical and clinical studies. As part of the stepwise approach recommended by regulatory agencies, the first step in the clinical evaluation of ...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2016.1171431
更新日期:2016-07-01 00:00:00
abstract::Monoclonal antibodies (mAb) have become a mainstay in tumor therapy. Clinical responses to mAb therapy, however, are far from optimal, with many patients presenting native or acquired resistance or suboptimal responses to a mAb therapy. MAbs exert antitumor activity through different mechanisms of action and we propos...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.22775
更新日期:2013-01-01 00:00:00
abstract::During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibo...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.1080/19420862.2016.1268307
更新日期:2017-02-01 00:00:00
abstract::There are currently ~25 recombinant full-length IgGs (rIgGs) in the market that have been approved by regulatory agencies as biotherapeutics to treat various human diseases. Most of these are based on IgG1k framework and are either chimeric, humanized or human antibodies manufactured using either Chinese hamster ovary...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.19868
更新日期:2012-05-01 00:00:00
abstract::Monoclonal antibodies are widely used for the treatment of cancer, inflammatory and infectious diseases and other disorders. Most of the marketed antibodies are monospecific and therefore capable of interacting and interfering with a single target. However, complex diseases are often multifactorial in nature, and invo...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.4.2.19000
更新日期:2012-03-01 00:00:00
abstract::High titer (>10 g/L) monoclonal antibody (mAb) cell culture processes are typically achieved by maintaining high viable cell densities over longer culture durations. A corresponding increase in the solids and sub-micron cellular debris particle levels are also observed. This higher burden of solids (≥15%) and sub-micr...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1007824
更新日期:2015-01-01 00:00:00
abstract::Antibody-drug conjugates (ADCs) that exploit the active metabolite SN-38, which is derived from the popular anticancer drug, irinotecan (a camptothecin that inhibits the nuclear topoisomerase I enzyme, inducing double-stranded DNA breaks during the mitotic S-phase of affected cells), represent a substantial advance in...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.1080/19420862.2019.1632115
更新日期:2019-08-01 00:00:00
abstract::Ch-mAb7F9, a human-mouse chimeric monoclonal antibody (mAb) designed to bind (+)-methamphetamine (METH) with high affinity and specificity, was produced as a treatment medication for METH abuse. In these studies, we present the preclinical characterization that provided predictive evidence that ch-mAb7F9 may be safe a...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.27620
更新日期:2014-03-01 00:00:00
abstract::The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide insight into the role of the immune system. The establishment of sy...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2019.1685350
更新日期:2020-01-01 00:00:00
abstract::Despite availability of biologic therapies, limited patient access to many of the most-effective cancer treatments affects overall health outcomes. To address this issue, many governments have enacted legislation for the approval of biosimilars. The term "biosimilar" refers to a biologic product that is developed to b...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.1080/19420862.2015.1008346
更新日期:2015-01-01 00:00:00
abstract::Monoclonal antibody (mAb) candidates from high-throughput screening or binding affinity optimization often contain mutations leading to liabilities for further development of the antibody, such as aggregation-prone regions and lack of solubility. In this work, we optimized a candidate integrin α11-binding mAb for deve...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2018.1475871
更新日期:2018-08-01 00:00:00
abstract::The current standard treatment for acute myeloid leukemia (AML) is chemotherapy based on cytarabine and daunorubicine (7 + 3), but it discriminates poorly between malignant and benign cells. Dose-limiting off‑target effects and intrinsic drug resistance result in the inefficient eradication of leukemic blast cells and...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2015.1007818
更新日期:2015-01-01 00:00:00
abstract::Tremendous knowledge has been gained in the understanding of various modifications of IgG antibodies, driven mainly by the fact that antibodies are one of the most important groups of therapeutic molecules and because of the development of advanced analytical techniques. Recombinant monoclonal antibody (mAb) therapeut...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.29883
更新日期:2014-01-01 00:00:00
abstract::Although there are currently more than 30 antibody-drug conjugates (ADC) in clinical development for the treatment of blood cancers and solid tumors, comparison of their clinical pharmacokinetics (PK) is challenging because of the large number of, and differences between, the targets, ADC constructs, dosing regimens, ...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.28965
更新日期:2014-07-01 00:00:00
abstract::Post-translational modifications can have a signification effect on antibody stability. A comprehensive approach is often required to best understand the underlying reasons the modification affects the antibody's potency or aggregation state. Monoclonal antibody 001 displayed significant variation in terms of potency,...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2016.1160179
更新日期:2016-05-01 00:00:00
abstract::The cervical mucosa of women who are highly exposed to HIV-1, yet remain persistently seronegative (HEPS), presents a unique opportunity to study the dynamics of an immune compartment potentially capable of preventing HIV-1 infection. Herein, we provide a detailed characterization of the immunoglobulin repertoire of c...
journal_title:mAbs
pub_type: 杂志文章
doi:10.4161/mabs.3.2.14858
更新日期:2011-03-01 00:00:00
abstract::Animal cell culture technology has advanced significantly over the last few decades and is now generally considered a reliable, robust and relatively mature technology. A range of biotherapeutics are currently synthesized using cell culture methods in large scale manufacturing facilities that produce products for both...
journal_title:mAbs
pub_type: 杂志文章,评审
doi:10.4161/mabs.2.5.12720
更新日期:2010-09-01 00:00:00
abstract::Plasmacytoid dendritic cells (pDCs) play a central role for both innate and adaptive antiviral responses, as they direct immune responses through their unique ability to produce substantial concentrations of type I interferon (IFNs) upon viral encounter while also activating multiple immune cells, including macrophage...
journal_title:mAbs
pub_type: 杂志文章
doi:10.1080/19420862.2018.1451283
更新日期:2018-05-01 00:00:00